Although both semaglutide and lanifibranor significantly lowered α-SMA levels, semaglutide had no effect on fibrosis histology in GAN DIO-NASH-HCC mice. This evidence concerns the gene ACTA1 and metabolic dysfunction-associated steatohepatitis.